Skip to content

Effectiveness of Antrodia Cinnamomea Mycelia on Improving Immune Response in Subhealth People

Effectiveness of Antrodia Cinnamomea Mycelia on Improving Immune Response in Subhealth People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05728918
Enrollment
25
Registered
2023-02-15
Start date
2023-03-01
Completion date
2024-05-30
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cold, Fatigue Syndrome, Chronic

Brief summary

This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people.

Detailed description

This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people: a randomized, double-blind, placebo-controlled, and parallel clinical investigation.

Interventions

DIETARY_SUPPLEMENTAntrodia cinnamomea mycelia

Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months

DIETARY_SUPPLEMENTPlacebo

Placebo capsule, two capsules/day (600 mg/day) for 3 months

Sponsors

Greenyn Biotechnology Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects are easy to feel fatigued * Subjects have poor sleep quality

Exclusion criteria

* Pregnant women or preparing for pregnancy. * Lactating women. * Women gave birth 6 months before the study. * Poor kindy and livers funcitons * Severe cardiovascular or other chronic diseases * Alcohol abuser * Using immune-associated supplements

Design outcomes

Primary

MeasureTime frameDescription
Immune analysisBaseline up to 4 weeksChanges in T cell markers of 29 participants will be analyzed between baseline and week 4.
Antibody analysisBaseline up to 4 weeksChanges in IgA levels of 29 participants will be analyzed between baseline and week 4.
Cytokine analysisBaseline up to 4 weeksChanges in IL-1beta levels of 29 participants will be analyzed between baseline and week 4.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026